Profile data is unavailable for this security.
About the company
Akeso Inc is an investment holding company mainly engaged in the research and development of biological products. The Company is dedicated to addressing global unmet medical needs in oncology, immunology and other therapeutic areas. The Company's main products include AK104, AK105, AK112 and AK109. The Company conducts its businesses within the China market and to overseas markets.
- Revenue in HKD (TTM)4.86bn
- Net income in HKD2.18bn
- Incorporated2019
- Employees2.78k
- LocationAkeso IncNo.6 Shennong RoadHuoju Development ZoneZhongshan 528437ChinaCHN
- Phone+86 76 089873998
- Fax+86 76 089873900
- Websitehttps://www.akesobio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ascentage Pharma Group International | 238.54m | -994.69m | 8.53bn | 583.00 | -- | 121.13 | -- | 35.75 | -3.51 | -3.51 | 0.845 | 0.2237 | 0.0833 | 2.38 | 2.22 | 409,166.20 | -34.73 | -44.93 | -52.82 | -57.04 | 86.24 | 87.68 | -417.02 | -976.10 | 1.42 | -15.03 | 0.9622 | -- | 5.85 | 100.76 | -4.84 | -- | 2.82 | -- |
| Keymed Biosciences Inc | 380.51m | -386.16m | 9.47bn | 897.00 | -- | 2.95 | -- | 24.89 | -1.48 | -1.48 | 1.44 | 11.47 | 0.0906 | 0.7314 | 26.14 | 424,203.30 | -9.16 | -- | -10.05 | -- | 89.59 | -- | -101.04 | -- | 9.18 | -- | 0.123 | -- | 253.87 | -- | -16.63 | -- | -- | -- |
| InnoCare Pharma Ltd | 793.63m | -678.35m | 9.96bn | 1.09k | -- | 1.13 | -- | 12.55 | -0.4022 | -0.4022 | 0.4703 | 4.36 | 0.073 | 1.39 | 3.39 | 728,770.90 | -6.38 | -13.41 | -8.08 | -15.36 | 82.61 | 85.99 | -87.42 | -172.16 | 4.13 | -- | 0.1582 | -- | 18.09 | 240.36 | 28.80 | -- | 66.20 | -- |
| RemeGen Co Ltd | 1.16bn | -1.62bn | 19.27bn | 3.62k | -- | 3.15 | -- | 16.66 | -3.01 | -3.01 | 2.15 | 6.87 | 0.1864 | 0.4005 | 4.31 | 319,891.80 | -26.17 | -18.66 | -31.75 | -23.75 | 76.48 | 81.94 | -140.43 | -102.88 | 1.31 | -64.32 | 0.2682 | -- | 40.16 | 148.65 | -51.30 | -- | 59.07 | -- |
| Genscript Biotech Corp | 6.56bn | -745.57m | 19.53bn | 6.94k | -- | 1.79 | -- | 2.98 | -0.3539 | -0.3539 | 3.11 | 5.12 | 0.283 | 7.59 | 5.45 | 945,048.00 | -11.97 | -18.34 | -18.27 | -26.15 | 48.78 | 54.68 | -42.30 | -64.91 | 4.65 | -- | 0.1694 | -- | 34.17 | 29.44 | 57.91 | -- | 17.14 | -- |
| Akeso Inc | 4.86bn | 2.18bn | 33.68bn | 2.78k | 14.95 | 6.49 | 15.03 | 6.92 | 2.60 | 2.60 | 5.81 | 6.00 | 0.6168 | 0.3749 | 15.98 | 1,750,867.00 | 26.47 | -11.59 | 31.40 | -13.87 | 96.96 | -- | 42.91 | -42.49 | 4.39 | 19.18 | 0.3983 | -- | 440.35 | 337.43 | 273.60 | -- | 63.99 | -- |
| Sichuan Kelun-Biotech Biophrmctcl Co Ltd | 1.66bn | -616.96m | 36.41bn | 1.42k | -- | 14.31 | -- | 22.00 | -2.78 | -2.78 | 7.55 | 11.42 | -- | -- | -- | 1,169,903.00 | -- | -- | -- | -- | 49.28 | -- | -37.27 | -- | 2.47 | -34.90 | 0.0251 | -- | 91.62 | -- | 6.81 | -- | -- | -- |
| WuXi Biologics (Cayman) Inc | 18.31bn | 3.65bn | 46.76bn | 12.74k | 13.40 | 1.10 | 8.78 | 2.55 | 0.84 | 0.84 | 4.21 | 10.22 | 0.321 | 5.04 | 3.02 | 1,436,813.00 | 6.73 | 8.28 | 8.47 | 10.25 | 40.08 | 43.25 | 20.96 | 27.46 | 2.54 | -- | 0.0939 | 0.00 | 11.56 | 46.38 | -23.09 | 40.07 | 20.32 | -- |
| Beigene Ltd | 21.57bn | -6.13bn | 126.42bn | 10.00k | -- | 4.59 | -- | 5.86 | -4.55 | -4.55 | 15.81 | 19.30 | 0.4753 | 1.87 | 7.42 | -- | -13.50 | -26.72 | -18.48 | -33.85 | 74.76 | 83.19 | -28.39 | -120.76 | 1.84 | -- | 0.2339 | -- | 73.65 | 65.47 | 56.00 | -- | 33.46 | -- |
Data as of Jul 09 2024. Currency figures normalised to Akeso Inc's reporting currency: Hong Kong Dollar HKD
17.68%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Green Court Capital Management Ltd.as of 31 Jan 2024 | 43.45m | 5.02% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 27.25m | 3.15% |
| The Vanguard Group, Inc.as of 06 Jun 2024 | 19.24m | 2.22% |
| Zhong Ou Asset Management Co., Ltdas of 31 Dec 2023 | 11.96m | 1.38% |
| GF Fund Management Co., Ltd.as of 31 Dec 2023 | 11.53m | 1.33% |
| Harvest Fund Management Co., Ltd.as of 31 Dec 2023 | 10.46m | 1.21% |
| BlackRock Fund Advisorsas of 06 Jun 2024 | 9.72m | 1.12% |
| Allianz Global Investors Asia Pacific Ltd.as of 31 May 2024 | 7.03m | 0.81% |
| The Caisse de d�p�t et placement du Qu�becas of 31 Dec 2023 | 6.27m | 0.72% |
| Bank of China Investment Management Co., Ltd.as of 31 Dec 2023 | 6.12m | 0.71% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
